계명대학교 의학도서관 Repository

표재성 방광암에서 반복 BCG 방광내 주입요법의 치료효과와 적응중 선택

Metadata Downloads
Author(s)
류동수박철희이성준Dong Soo RyuChoal Hee ParkSung Choon Lee
Keimyung Author(s)
Park, Choal HeeLee, Sung Joon
Department
Dept. of Urology (비뇨의학)
Journal Title
대한비뇨기과학회지
Issued Date
1994
Volume
35
Issue
5
Abstract
Although initial and additional course of intravesical bacillus Calmette-Guerin (BCG) immunotherapy have proved effective in the treatment and prophylaxis of superficial bladder cancers, including carcinoma in situ, a significant minority of patients will fail such therapy and criteria for selection of patients who may benefit from an additional course of BCG have not yet been established. In an attempt to identify patients who are likely to respond, we analyzed our experience in patients with superficial bladder cancer treated with a subsequent course of BCG. Of 86 patients who received an initial once a week for 6-week and once a month for 3-month of intravesical BCG for superficial transitional cell carcinoma of the bladder 18(21 per cent) were treated with another course. First course of BCG was successful in 50 (66 per cent) of 76 patients treated for prophylaxis and 4 (40 per cent) of 10 treated for carcinoma in situ. The response rate for the total patients population treated with first course was 62.8 per cent (54 of 86). Of 32 patients who failed the initial treatment course 18 were given an additional BCG therapy, subsequent progression of disease occurred in 2 patients( 11 per cent). Of the l6 patients (89 per cent) without progression 10 (56 percent) had a complete response and 6 (33 per cent) had new tumors. and they were rendered free of disease after transurethral resection. The median interval between course 1 and 2 of intravesical BCG was 12 months (range, 4-40 months) and the median followup after course 2 was 22 months (range, 4-69 months). The median duration of response to course 1 of BCG was shorter for patients with disease progression or recurrence after course 2 than for those with no progression or recurrence (8 and 15 months) . The results suggest that initial and subsequent course of intravesical BCG are effective in the treatment and prophylaxis of superficial bladder cancer, including carcinoma in situ, and a subsequent treatment with BCG is most likely to be useful in patients who have a sustained response to the initial treatment.
Key word : Superficial bladder cancer, BCG.
Alternative Title
Results and Indication of Patients with Superficial Bladder Cancer to a Second Course of Intravesical Bacillus Calmette-Guerin
Keimyung Author(s)(Kor)
박철희
이성준
Publisher
School of Medicine
Citation
류동수 et al. (1994). 표재성 방광암에서 반복 BCG 방광내 주입요법의 치료효과와 적응중 선택. 대한비뇨기과학회지, 35(5), 492–497.
Type
Article
ISSN
2005-6737
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/38804
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.